Clinical Trial Update: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• FOLFIRINOX
• PF-04136309 (PF-04136309)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pancreatic Neoplasms | Phase 1 | Status: COMPLETED